SCHEMBL6142880

SCHEMBL6142880

CC(C)(C)C(=O)Oc1ccc2c(c1)OC[C@H](c1ccccc1)[C@]2(O)Cc1ccc(O)cc1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 1/20 0.38
ADRA2C P18825 1/20 0.38
SLC6A4 P31645 1/20 0.38
ELANE P08246 5/20 0.36
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
CYP19A1 P11511 1/20 0.34
HIF1A Q16665 4/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
ESR1 P03372 2/20 0.33
ESR2 Q92731 2/20 0.33
MAPT P10636 1/20 0.32
HSD17B10 Q99714 1/20 0.32
P4HB P07237 1/20 0.32
GAA P10253 1/20 0.32
HTT P42858 1/20 0.32
ESRRG P62508 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6142878 1.00 ADRA2A (0.38) ADRA2AADRA2CSLC6A4ELANEMEN1
SCHEMBL6142881 1.00 ADRA2A (0.38) ADRA2AADRA2CSLC6A4ELANEMEN1
SCHEMBL6144599 0.93 HIF1A (0.42) ADRA2AADRA2CSLC6A4HIF1A
SCHEMBL6144595 0.93 HIF1A (0.42) ADRA2AADRA2CSLC6A4HIF1A
SCHEMBL6143620 0.92 ALOX15 (0.37) ADRA2AADRA2CSLC6A4ELANEMEN1
SCHEMBL6143520 0.88 HIF1A (0.40) CYP19A1HIF1A
SCHEMBL6142892 0.85 ESR1 (0.52) ADRA2ASLC6A4ESR1ESR2HTT
SCHEMBL6142894 0.85 ESR1 (0.52) ADRA2ASLC6A4ESR1ESR2HTT
SCHEMBL6142890 0.85 ESR1 (0.52) ADRA2ASLC6A4ESR1ESR2HTT
SCHEMBL6143036 0.78 ESR1 (0.53) ADRA2ASLC6A4ESR1ESR2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951883-B2 2H-1-benzopyran derivatives processes for their preparation and pharmaceutical compositions thereof CHIESI FARMACEUTICI S.P.A. (IT) 2005-10-04 US disclosed
EP-1355906-B1 2H-1-BENZOPYRAN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF CHIESI FARMA SPA (IT) 2005-01-12 EP disclosed
US-20040106595-A1 2H-1-benzopyran derivatives processes for their preparation and pharmaceutical compositions thereof CHIESI FARMACEUTICI S.P.A. (IT) 2004-06-03 US disclosed
EP-1229036-A1 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof CHIESI FARMACEUTICI S.p.A. (IT) 2002-08-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106595-A1 2H-1-benzopyran derivatives processes for their preparation and pharmaceutical compositions thereof CYP19A1, BRCA1, HPD ADRA2A 997/4885ADRA2C 1089/4885SLC6A4 4690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.